Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II RUTI in high-risk non–muscle-invasive bladder cancer receiving BCG
2016-004311-12Phase 2Active
- Sponsor
- Archivel Farma
- Start
- Dec 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bladder cancer comparing RUTI + BCG with Placebo + BCG (2 arms). Primary endpoints: Systemic Th1 immune response and Mucosal immunological response. Started Dec 2016; status: active.
02
Drugs
RUTI vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2016-004311-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004311-12.